Abstract
Background:Nintedanib (NIN) is an antifibrotic drug first approved for the treatment of idiopathic pulmonary fibrosis (IPF) and then for systemic sclerosis-associated interstitial lung disease (SSc-ILD) which has proved to slow...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have